Novo Taps OpenAI to Speed Development of New Obesity Drugs

Novo Nordisk A/S will integrate OpenAI’s artificial intelligence across the company to accelerate drug development.

The Danish drugmaker didn’t disclose financial terms of the partnership announced Tuesday, which adds to Novo’s existing AI efforts that include a research-focused deal announced last year with Nvidia Corp.